Compounds 1-252
Pre-clinical- Indications
- Multiple sclerosis, Transplant rejection, Acute respiratory distress syndrome, Adult respiratory distress syndrome, Influenza, Ulcerative colitis, Crohn's disease
Company intelligence / Profile preview
Helioeast Pharmaceutical is a China-based pharmaceutical company focused on the R&D, production, and sales of chemical generic drugs and modern TCMs. The company has established R&D centers specializing in new drug release technologies and targeted drug delivery. Its pipeline includes small molecule drugs targeting KDM1A for acute myeloid leukemia and S1PR1 antagonists for systemic lupus erythematosus, both in Phase 1 clinical trials. The company has patented novel oxa-spirocyclic KDM1A inhibitors with potential utility in oncology, particularly AML.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Helioeast Pharmaceutical.